Companies
Nofima
peptide bioactivity research — pilot lines and clinical peptide trials for diabetes.
- Country
- Norway
Coverage
| CN | EU | US | |
|---|---|---|---|
| aquaculture-seafood | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | The Research Council of Norway (projects included TailoTides, Pepfishing) | nofima.com |
| Revenue | NOK 736 million (2024) | nofima.com |
| Headcount | 371 employees | nofima.com |
| Production site | Tromsø, Norway (Biotep facility at Nofima headquarters) | biotep.no · nofima.com |
| Capacity | Can handle volumes from small batches up to 1,000 kg; flexible mini-factory scale | biotep.no |
| Regulatory approval | Biotep is approved by the Norwegian Food Safety Authority (Mattilsynet) | biotep.no |
Independent sources: biotep.no
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Marine peptides & nutraceuticals | aquaculture-seafood | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.